Perspective Therapeutics, Inc.

Perspective Therapeutics is a clinical-stage radiopharmaceutical company pioneering advanced, image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer. The company utilizes a proprietary technology platform that employs the alpha-emitting isotope Lead-212 (212Pb) to deliver potent radiation directly to cancer cells via high-affinity targeting peptides. In addition to its therapeutic pipeline, the company develops complementary imaging diagnostics using the radiotracer Pb-203. This 'theranostic' approach allows physicians to confirm tumor target expression and tissue distribution prior to therapy, enabling personalized patient selection and optimized outcomes. The company was formed in February 2023 following the merger of Viewpoint Molecular Targeting, Inc. and Isoray, Inc.